Reports Q3 revenue $11M, consensus $15.5M. Cash and cash equivalents as of September 30, 2025 were $56.4 million. The company continues to expect that its capital resources will be sufficient to support its current operating plan commitments into mid-2026
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana Therapeutics downgraded to Market Perform from Outperform at William Blair
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Mersana Therapeutics downgraded to Neutral from Buy at Guggenheim
- Mersana downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating on DAWN’s Acquisition of Mersana Therapeutics: Balancing Opportunities and Risks Amid ACC Focus